Join us on Monday, July 27 for the live webinar
5:00 PM – 6:30 PM ET
1.5 AMA PRA Category 1 Credits^TM

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in this live webinar.

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Grail Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, and Taiho Oncology Inc.

Topics to Be Discussed

• Published research data exploring the correlation between tumor location and response to specific therapeutic interventions for patients with mCRC
• Key efficacy findings from the Phase III BEACON CRC trial comparing encorafenib/cetuximab with or without binimetinib to irinotecan/cetuximab or FOLFIRI/cetuximab for patients with mCRC and BRAF V600E mutations
• Frequency and severity of toxicities observed with encorafenib/binimetinib/cetuximab in BEACON CRC; rates of treatment discontinuation due to tolerability issues
• FDA approval of encorafenib/cetuximab for patients with mCRC and BRAF V600E mutations; optimal integration into practice
• Recent data from the Phase II DESTINY-CRC01 study of trastuzumab deruxtecan for patients with HER2-expressing mCRC
• Ongoing investigation of other novel HER2-directed approaches (eg, lapatinib/trastuzumab, tucatinib/trastuzumab, T-DM1) for patients with mCRC
• Optimal sequencing of regorafenib, TAS-102 and EGFR antibody therapy for patients with mCRC; use of clinical characteristics to inform this decision
• Available data with and potential role of TAS-102 in combination with other systemic agents in mCRC or in earlier disease stages
• Mechanism of action of and early efficacy findings with napabucasin for patients with mCRC; design, eligibility and estimated completion date of the Phase III CanStem303C study evaluating napabucasin in combination with FOLFIRI for previously treated mCRC
• Published data supporting the FDA approvals of nivolumab, pembrolizumab and nivolumab/ipilimumab for patients with MSI-H/dMMR mCRC; patient selection for anti-PD-1 monotherapy versus combined anti-PD-1/anti-CTLA-4 antibody therapy
• Design, eligibility criteria and major efficacy and safety outcomes from Phase III studies (eg, KEYNOTE-062, KEYNOTE-181, ATTRACTION-3) evaluating anti-PD-1/PD-L1 antibodies in advanced gastroesophageal cancers
• Results from the Phase III KEYNOTE-177 study of front-line pembrolizumab versus chemotherapy for MSI-H/dMMR mCRC; implications for clinical practice
• Biologic rationale for the investigation of regorafenib in combination with nivolumab for patients with microsatellite-stable mCRC
• Key efficacy and safety outcomes from the Phase Ib REGONIVO trial evaluating regorafenib/nivolumab for patients with mCRC or metastatic gastric cancer; development plans for this combination
• Current role of immune checkpoint blockade for patients with metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancers
• Integration of ramucirumab into current clinical algorithms for metastatic gastric/GEJ cancer
• Major efficacy and safety outcomes from the Phase III TAGS study of TAS-102 for heavily pretreated metastatic gastric cancer
• FDA approval of and patient selection for TAS-102 in metastatic gastric cancer
• Key findings from the randomized Phase II DESTINY-Gastric01 study of trastuzumab deruxtecan in patients with HER2-positive advanced gastric or GEJ adenocarcinoma; FDA breakthrough therapy designation and potential clinical role

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

Learning Objectives

• Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer (mCRC), considering the patient’s biomarker profile (BRAF, MSI, HER2), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
• Appreciate published research data documenting the efficacy of combined BRAF/MEK/EGFR inhibition for patients with relapsed/refractory CRC and a BRAF-V600E mutation to optimally incorporate this therapeutic strategy into current clinical algorithms.
• Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection and sequence of systemic therapy for patients with locally advanced or metastatic gastric/gastroesophageal cancer.
• Recall the biologic rationale for and available data with the use of trastuzumab deruxtecan for patients with previously treated HER2-positive CRC or gastric/gastroesophageal cancers, and discern the current and potential future clinical applicability of this treatment strategy.
• Recall the FDA approvals of anti-PD-1 and anti-CTLA-4 antibodies for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) mCRC, and appropriately integrate these agents into current treatment algorithms.
• Describe ongoing research to validate the potential benefit of immune checkpoint inhibitors in combination with chemotherapy, targeted therapy or other immunotherapies for patients with MSI-H/dMMR and MSI-stable mCRC, and use this information to guide trial design and referral.
• Devise a rational approach to the incorporation of TAS-102 into the treatment algorithms for previously treated locally advanced or mCRC or gastric/gastroesophageal cancers.
• Recall new data with investigational agents demonstrating promising activity in gastrointestinal cancers, and use this information to refer appropriate patients for participation in ongoing trials.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Bendell — Advisory Committee and Consulting Agreements (To Institution): Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Piper Biotech, Prelude Therapeutics, Relay Therapeutics, Samsung Bioepis, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Research Funding to Institution: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Therapeutics, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, Bayer HealthCare Pharmaceuticals, Beigene, Bellicum Pharmaceuticals Inc, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, CALGB, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceutical Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Morphotek Inc, Nektar, NGM Biopharmaceuticals, Novartis, Novocure, Numab Therapeutics, OncoGenex Pharmaceuticals Inc, Oncologie, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Relay Therapeutics, Revolution Medicines, Rgenix, Sanofi Genzyme, Scholar Rock, Seattle Genetics, Shattuck Labs, Sierra Oncology, Stemcentrx, SynDevRx Inc, Synthorx, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad, Zymeworks. Dr Denlinger — Advisory Committee: Astellas, Exelixis Inc; Consulting Agreements: Bristol-Myers Squibb Company, Merck; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Bristol-Myers Squibb Company, Exelixis Inc, Lilly, MacroGenics Inc, Sanofi Genzyme, Zymeworks. Dr Grothey — Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Taiho Oncology Inc, Takeda Oncology; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
— Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Grail Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, and Taiho Oncology Inc.